Drug intelligence / Profile preview

yohimbine + hydrocortisone

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous

Overview

A pharmacological combination consisting of yohimbine, an alpha-2-adrenergic receptor antagonist, and hydrocortisone, a glucocorticoid. This combination has been studied for its effects on panic symptoms and attention to social threat cues. Research suggests that hydrocortisone may attenuate the panic symptoms induced by yohimbine. The combination has shown unique effects on attentional bias to emotional stimuli compared to either drug alone.

Other names: Active stressorYohimbine hydrochloride + Hydrocortisoneactive stressor-Wayne State University-opioid dependence-opioid use disorder

Targets

ADRA2A (α2A)I2R (Imidazoline I2 receptor)GR (Glucocorticoid receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on yohimbine + hydrocortisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yohimbine + hydrocortisone.

Explore the full profile